Polymorphic forms of rifaximin and clinical efficacy
Milan Lukáš1
+ Affiliation
Literature
1. DuPont HL. Review article: the antimicrobial effects of rifaximin on the gut microbiota. Aliment Pharmacol Ther 2016; 43(Suppl 1): 3–10. doi: 10.1111/ apt.13434.
2. Cheng J, Shah YM, Ma X et al. Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther 2010; 335(1): 32–41. doi: 10.1124/ jpet.110.170225.
3. Lukáš M. Rifaximin v terapii idiopatických střevních zánětů. Gastroent Hepatol 2021; 75(1): 51–54. doi: 10.48095/ccgh202151.
4. Dharani S, Barakh SF, Afrooz F et al. Studying effect of glyceryl palmitostearate amount, manufacturing method and stability on polymorphic transformation and dissolution of rifaximin tablets. Int J Pharm 2020; 589: 119785. doi: 10.1016/j.ijpharm.2020.119785.
5. Toukabri I, Bahri S, Sfar S et al. Impact of crystal polymorphism of rifaximin on dissolution behaviour. Heliyon 2024; 10(5): e27131. doi: 10.1016/j.heliyon.2024.e27131.
6. Blandizzi C, Scarpignato C. Generic drugs in gastroenterology. Critical issues in bioequivalence and interference on therapeutic equivalence. Ther Perspect. 2014; 17: 1–43.